E-selectin-mediated dynamic interactions of breast-and colon-cancer cells with endothelial-cell monolayers
✍ Scribed by Aydin Tözeren; Hynda K. Kleinman; Derrick S. Grant; David Morales; Arthur M. Mercurio; Stephen W. Byers
- Book ID
- 102869429
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- French
- Weight
- 909 KB
- Volume
- 60
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
The molecular mechanisms involved in the dynamic interaction of human breast carcinoma cells with the endothelial cell lining of lymphatic vessels and post-capillary blood venules are largely unknown. In the present study, laminar flow assays were used to investigate the ability of various normal breast cells and of breast-and colon-tumor cells to adhere to human umbilical cord endothelial cell monolayen. MCF-I OA breast, MCF-7 and T-47D breast-carcinoma and clone A. RKO, and HT-29 coloncarcinoma cells accumulated and rolled, in the presence of flow. on tumor necrosis factor (TNF)-stimulated but not on unstimulated endothelial cell monolayers. Non-tumor and tumor cells continued to form transient adhesions with TNF-stimulated endothelial cells even when the flow rate was increased to levels found in arteries. Incubation of TNF-stimulated endothelial cells with an E-selectin-specific monoclonal antibody (MAb) partially or completely inhibited dynamic interactions and diminished adhesion strength, whereas integrin PIand integrin %-specific MAbs had no effect. A set of highly invasive breast-carcinoma cells (MDA-23 I, BT-549, HS-578t) neither adhered to nor rolled on resting or TNF-stimulated endothelial cell monolayen. However, after 5 min of static incubation, a fraction of these cells attached strongly to resting and TNF-stimulated endothelial cells and this static adhesion could not be blocked by an E-selectin-specific monoclonal antibody. Our results suggest that E-selectin is a major homing receptor in the metastasis of some breast and colon cancers.
📜 SIMILAR VOLUMES
## Abstract Over 70% of patients with advanced breast cancer will develop bone metastases for which there is no cure. Mesenchymal Stem Cells (MSCs) and their derivative osteoblasts are subpopulations of cells within the bone marrow environment, postulated as potential interacting targets for dissem